



Figure 1: Specific Ab Levels (IgG) in
Visceral Leishmaniasis Patients




009271 20150260

**Figure 2: Specific Ab Levels (IgM) in
Visceral Leishmaniasis Patients**




**Figure 3: Specific Ab Levels (IgG)
Cutaneous Leishmaniasis**



006211 0052260

Figure 4: Specific Ab Levels (IgM) in
Cutaneous Leishmaniasis Patients



09725182.112900

**Figure 5: Specific Ab Levels (IgG) in
Canines Infected with *L. chagasi***





Figure 6: Specific Ab Levels (IgM) in Canines Infected with *L. chagasi*



005211-28152260

006217 23152260




Figure 7: Western blot showing specific activity of Rabbit anti-leishmania PAb, normal human sera and sera from kala azar patients.

006217-28152260




Figure 8: Graph Depicting Specific Activity of the Competitive Ag-Capture ELISA Using Different Antigen and HRP-Labeled Antigen Conditions.

006217 28152260




Figure 9: Graph Depicting Specific Activity of the Competitive Ag-Capture ELISA While Titrating Labeled Antigen Under Different Coating and Blocking Conditions